GeoVax Labs, Inc. to Review Progress and Strategic Priorities During Biotech Showcase 2026 and J.P. Morgan Healthcare Conference Week

About this update from Geovax Labs, Inc.

[{"type":"image","caption":"","headline":"GeoVax Highlights 2026 as a Pivotal Year for Progress","size":{"original":{"width":140,"height":140,"url":"https://media.zenfs.com/en/newsmediawire_165/6b870301b9c37c9b2d12fc8f9b2a2ecc"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/CK3y_RQaAtNDQGf8lPQXOQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIxMDtoPTIxMDtjZj13ZWJw/https://media.zenfs.com/en/newsmediawire_165/6b870301b9c37c9b2d12fc8f9b2a2ecc","width":140,"height":140}}},{"type":"text","content":"ATLANTA, GA - January 6, 2026 (NEWMEDIAWIRE) - GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company advancing innovative immunotherapies and vaccines for cancer and infectious diseases, today announced that senior management will participate in investor and partner engagements during Biotech Showcase 2026 and the 44th Annual J.P. Morgan Healthcare Conference Week in San Francisco, January 12-15, 2026.","length":424,"tagName":"p"},{"type":"text","content":"During these premier investor forums, GeoVax leadership will highlight the Company's 2025 operational achievements, clinical pipeline progress, and strategic priorities for 2026, including key clinical catalysts, regulatory milestones, and business development related to the following programs and initiatives:","length":315,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"CM04S1 (COVID-19): Clinical status, translational data, and regulatory pathways for high-risk and immunocompromised populations.","length":128,"tagName":"p"}]},{"val":[{"type":"text","content":"Gedeptin(R) (Solid Tumors): Translational and clinical data supporting development in head & neck cancer and other high-value solid tumor indications.","length":154,"tagName":"p"}]},{"val":[{"type":"text","content":"GEO-MVA (Mpox & Smallpox): Regulatory progress, clinical strategy, and potential registration pathways supporting civilian and biodefense use.","length":146,"tagName":"p"}]},{"val":[{"type":"text","content":"Manufacturing Platform: Advancements in continuous cell-line manufacturing enabling scalable, resilient, and domestic vaccine production.","length":137,"tagName":"p"}]},{"val":[{"type":"text","content":"Business Development: Partnership and collaboration opportunities to support pipeline advancement and long-term value creation.","length":127,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"l...

More updates from Geovax Labs, Inc.